Abstract
Purpose: Tanezumab, a nerve growth factor antibody, is being developed to relieve the signs and symptoms of osteoarthritis (OA). This subgroup analysis explored the efficacy of subcutaneous tanezumab in patients with OA of different radiographic severities.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
